Skip to main content
Clinical Trials/NCT04156477
NCT04156477
Unknown
Not Applicable

Markers of Appetite Regulation During Exogenous Ketosis - a Placebo Controlled Randomized Study of Appetite Regulatory and Metabolic Markers After Intake of a Keto- or Glucogenic Drink.

Central Jutland Regional Hospital1 site in 1 country10 target enrollmentOctober 24, 2019
ConditionsKetosis

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Ketosis
Sponsor
Central Jutland Regional Hospital
Enrollment
10
Locations
1
Primary Endpoint
GLP-1 concentration
Last Updated
6 years ago

Overview

Brief Summary

The aim of this study is to investigate the relationship, if any, between markers of satiety, desire to eat, hunger, and metabolic markers of the regulation hereof during ketosis as compared with a Glucose-containing and a Placebo drink adjusted for taste.

Detailed Description

All subjects are, in random order, tested on three separate occasions with intake of weight adjusted and taste matched drink of i) a ketone ester, and ii) an isocaloric and -volumetric glucose drink, or iii) an isovolumetric tap water drink. Subjects are studied for five hours with baseline and blood sampling on multiple occasions. A satiety questionaire are included. Subjects are recruited through notice on website for this purpose. Sample size calculations were performed prior to inclusion (n=10). According to protocolized statistical plan, missing data will not be replaced and no imputation will occur. Data will be analyzed by applying a repeated measurements multilevel model with intervention, time and their interactions as categorical factors. Effects size are adjusted for small sample size.

Registry
clinicaltrials.gov
Start Date
October 24, 2019
End Date
December 2019
Last Updated
6 years ago
Study Type
Interventional
Study Design
Crossover
Sex
Male

Investigators

Sponsor
Central Jutland Regional Hospital
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Males aged 18-65 years
  • BMI 20-35 kg/m2
  • Expected ease of catheter insertion
  • Oral and written informed consent

Exclusion Criteria

  • Inability to fully understand the consent including consent forms
  • Inability to cooperate to the trial
  • Any electrolyte disorders, kidney disease or otherwise compromised renal function including excess risk hereof, e.g. hypertension, albuminuria, autoimmune disease, family history of kidney disease
  • Any liver or bile disease including excess risk hereof, e.g. hepatotoxic drugs, alcohol abuse disorder, gallstones, pancreatitis, autoimmune disease, family history of liver disease
  • Diabetes mellitus or any metabolic and/or hormonal disease including diagnosed/undiagnosed reactive hypoglycemia or similar disorders. This includes treatment with drugs, dietary supplement with inference on key metabolic or hormonal markers, e.g. insulin, glukagon, lipids, and GLP-1
  • Any use of illegal or otherwise use of medicinal products without prescription
  • Anemia or other know disease of the hematopoietic system
  • Previous bariatric surgery
  • Previous myocardial infarction or uncontrolled myocardial ischemia
  • Recent intended/unintended weight loss

Outcomes

Primary Outcomes

GLP-1 concentration

Time Frame: 5 hours

Development of GLP-1 concentration during ketosis as compared after intake of a ketogenic vs a glucogenic drink vs a control drink, respectively.

Acyl ghrelin concentration

Time Frame: 5 hours

Development of acyl ghrelin concentration during ketosis as compared after intake of a ketogenic vs a glucogenic drink vs a control drink, respectively.

Secondary Outcomes

  • Satiety, desire to eat, and perceived hunger sensation(5 hours)
  • Insulin concentration(5 hours)
  • Glucose concentration(5 hours)
  • Free fatty acids concentration(5 hours)

Study Sites (1)

Loading locations...

Similar Trials